|
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors. |
| |
|
Research Funding - Merck (Inst) |
| |
|
Research Funding - BIND Biosciences (Inst); Celgene (Inst); Genentech/Roche (Inst); Janssen (Inst); Plexxikon (Inst) |
| |
|
|
Consulting or Advisory Role - Celgene |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Daiichi Sankyo; Merck |
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo |
Travel, Accommodations, Expenses - Daiichi Sankyo; Merck |
| |
|
|
Travel, Accommodations, Expenses - Plexxikon |
| |
|
|
Stock and Other Ownership Interests - Merck |
Research Funding - Plexxikon |
Travel, Accommodations, Expenses - Plexxikon |
| |
|
|
Patents, Royalties, Other Intellectual Property - Plexxikon |
Travel, Accommodations, Expenses - Plexxikon |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company |
Consulting or Advisory Role - Amgen; Merck |
| |
|
Consulting or Advisory Role - Amgen; Emergent BioSolutions (Inst); Novartis (Inst); Vaccinex |
Research Funding - Genentech (Inst); Pfizer (Inst); Plexxikon (Inst) |